mav set em free initi outperform
initi coverag outperform rate pt lead
candid mavorixafor first-in-class oral antagonist favor safeti
profil posit address sever rare chronic disord stem
immunodefici current lack effect option expect initi approv
whim syndrom global registr trial enrol cautious
optimist role waldenstrm macroglobulinemia clinic data earli
clinic readout sever congenit neutropenia anticip mav
produc support data add-on therapi oncolog set one
partnership land may follow trade ev
ampl cash reach sever key mileston view attract
caus trap white blood cell bone marrow result low circul level
impair abil clear infect especi hpv viru underli wart
certain mucos cancer mavorixafor significanli rais system level
clearli seen phase along meaning sustain reduct wart
burden infect rate
registr trial underway prior data predict success global placebo-
control whim top-lin data anticip
collabor facilit enrol well help build
patient registri market exclus expect late mav fda
breakthrough therapi adult orphan design whim syndrom
waldenstrm second opportun also clear target rational
form nhl annual us/eu incid patient
poorli respond soc imbruvica due mutat
dose-escal imbruvica commenc immin
evalu treatment-refractori double-mut patient clinic respons
strateg collabor leukemia lymphoma societi
addit clinical-stag opportun mavorixafor also explor
potenti therapi sever congenit neutropenia rare disord character
frequent fever infect birth clinic poc next year could
enabl expedit registr path oncolog mav appear enhanc tki
axitinib efficaci ccrcc pursu add development/commerci
partnership follow abbisko deal select asian market
get genzyme/anorm band back togeth prior
involv approv antagonist sanofi-genzym
mozobil iv stem cell mobil leadership distinguish deep industri
domain experi
year price histori
develop
immun cell traffick treat cancer
rare diseas
analyst certif import disclosur see disclosur
believ market underappreci potenti
mavorixafor hold treatment whim syndrom
waldenstrm macroglobulinemia think probabl
success program higher market valu
expect de-risk clinic trial data move stock
higher time also forese diagnosi rate treatment
improv time avail genet test
target therapi avail physician
success whim diagnos popul grow
chanc success
waldenstrom
macroglobulinemia treat dual mutant popul effect
partner cancer asset modest non-dilut fund
enrol updat whim syndrom
phase read-out scn
phase read-out wm
ind expect
whim exce patient us alon
glioblastoma better target hold valu
expect
combin therapi waldenstrm macroglobulinema could
file proof-of-concept phase
treatment scn could hold promis expect
whim syndrom popul could remain constrain
expect base physician diagnos
antagon wm combin ibrutinib could fail
partner may fail materi mavorixafor cancer indic
may need rais capit equiti market
price target calcul deriv sum-of-the-part risk-adjust dcf model year assign success
whim success wm success scn discount cash flow discount rate add pipelin
valu includ net cash share price assum price launch gross-to-net discount result net
price assum royalti cancer asset assign termin valu
risk includ failur mavorixafor meet primari endpoint phase whim trial disappoint trial unexpect
industri competit regulatori surpris could add delay increas risk approv need build sales/distribut
infrastructur addit capit requir obtain approv achiev profit
tabl content
clinic develop lead candid mavorixafor
pharmaceut pursu novel approach treatment primari
immunodefici cancer
mavorixafor first-in-class orally-administ small molecul
antagonist chemokin receptor receptor express
surfac white blood cell neutrophil lymphocyt
togeth ligand play key role traffick
overstimul axi caus matur immun cell
becom immobil within bone marrow prevent
migrat circul beyond perform
import protect function result immunodefici greatli
increas suscept infect block abnorm
signal mavorixafor prevent white blood cell
trap enabl releas bloodstream restor
xfor develop program led on-going phase registr
trial whim syndrom wart hypogammaglobulinemia infect
myelokathexi rare primari immunodefici caus genet
mutat caus receptor hyperfunct
hallmark frequent viral bacteri infect includ extens
wart go away usual intervent well hear
loss recurr ear infect wart caus human
papilloma viru hpv type drive malign tumor
format necessit disfigur surgic resect therapi
approv whim syndrom medic use
provid modest symptomat benefit target underli
biolog defect mavorixafor fda orphan drug breakthrough
therapi design whim syndrom
much enthusiasm mavorixafor whim come open-
label phase studi patient dose-escal result
show sever low level wbc entri increas drug
maintain level kept seven evalu patient
consist sever rang period maximum time
threshold tat measur one month addit wart
burden decreas dramat year therapi overal infect
rate typic peopl whim mavorixafor
abl escal upper end specifi daili dose rang
good toler max
global random double-blind phase evalu mavorixafor
daili similar popul enrol maximum
patient facilit genet test provid cost
patient primari immunodefici partner support
jeffrey model foundat primari endpoint neutrophil tat
averag four assess one year drug vs placebo top
line data expect assum success expect mavorixafor
launch treatment whim us europ
case whim syndrom reportedli publish
literatur actual preval may run us
alon believ mavorixafor aggreg net sale
opportun us europ
waldenstrm macroglobulinemia rare form non-hodgkin
lymphoma much common whim estim
preval us eu addit high frequenc
oncogen mutat gene approxim also
harbor whim-lik mutat predict much poorer clinic
respons jnj imbruvia current treatment standard
double-mut would appear stand benefit mavorixafor
dose-escalation/expans phase trial w/imbruvica patient
refractori recurr diseas begin come week efficaci
assess base respons top line data
report posit next step may approval-en trial
studi subject strateg collabor leukemia
also conduct phase exploratori trial mavorixafor
sever congenit neutropenia scn assess respond similar
whim syndrom patient scn abnorm low level
although neutrophil level typic less sever depress vs whim
patient suffer frequent fever bacteri infect includ
pneumonia oral ulcer well tooth loss reflect inadequ
protect oral environ result expect
suffici proof-of-concept could pave way registr trial pend
addit govern immun cell migrat bone marrow
pathway broadli appear play key role
microenviron solid tumor abnorm high
concentr disrupt immun cell traffick increas risk
cancer growth metastasi phase trial pfizer inlyta
advanc clear cell renal cell carcinoma result recent
present esmo support mavorixafor potenti enhanc clinic
respons establish anti-canc agent expect pursu
partner strategi develop oncolog exampl
partner china right mavorixafor abbisko
therapeut privat solid tumor indic
mavorixafor like reach market whim
reason chanc success double-mut waldenstrm well
addit therapeut potenti immunodefici well
cancer yet trade ev view inexpens
price target deriv probability-of-success adjust
discount cash flow valuat mavorixafor indic model
revenu gener assign termin valu
estim probabl success whim scn
wm respect model peak penetr address patient
popul whim scn wm
pre-clin asset assign pipelin valu assum
non-gbm cancer indic partner royalti non-dilut
fund price target calcul use share order
account dilut share one year
model modest growth address patient popul year
approxim whim patient scn patient
wm patient smaller address portion
patient expect subpopul scn patient
wm patient note publicli state
epidemiolog whim impli patient
us alon diagnos popul increas
total effect therapi market choos
conserv consid approxim patient
report clinic literatur
whim popul could exceed patient us
mavorixafor cancer especi glioblastoma well sever
congenit neutropenia may attract expect
waldenstrm macroglobulinemia potenti file phase
treatment scn subpopul could larger
may receiv signific royalti model
price expect mavorixafor may low
whim syndrom popul size could fail develop
antagon combin ibrutinib could fail show
improv efficaci mutant patient waldenstrm
partner could fail materi progress within combin
therapi solid tumor could stall lead end compani
investig mavorixafor tool oncolog would forc
equiti fund market
delay trial data would extend time need
support busi without revenu
clinic stage pharmaceut compani
focus develop novel therapi rare disord
immunodefici came part sanofi-genzym
restructur goal develop mavorixafor treatment rare
disord compani owe sanofi estim royalti
lead product mavorixafor current evalu four clinic
studi wart hypogammaglobulinemia infect myelokathexi
congenit neutropenia scn clear cell renal cell carcinoma ccrcc
compani also two preclin asset evalu
glioblastoma multiform second-gener version
mavorixafor oral alloster antagonist receptor
chemokin receptor locat
leukocyt express mani tissu includ bone
marrow strongli chemotact leukocyt mavorixafor design
inhibit overstimul pathway
exhibit mechan action
mavorixafor half-lif hour allow daili oral dose
shown favor safeti profil far minim side effect
seen includ dri mouth nausea dri eye nasal dryness
predomin signal retain cell within
bone marrow strong chemotact natur overstimul
lead excess bind bind affect number
diseas notabl whim syndrom also play role immun cell
traffick across tissu overexpress autosom
also overexpress mani cancer
shown play pivot role tumor develop metastasi
variou sourc mavorixafor evalu combin
tyrosin kinas inhibitor axitinib treatment clear cell renal carcinoma
american associ cancer research opco research
plerixafor approv antagonist market mobil
wbc plerixafor genzym earlier gener antagonist
current approv combin g-csf mobil
hematopoiet stem cell collect autolog transplant
plerixafor half-lif hour durat half-lif
hypothes limit factor plerixafor abil stimul
adapt immun respons great impedi effect
disord wish treat plerixafor also subcutan
inject low tissu distributionfactor signific usag
whim immunodefici disord
notabl antagonist clinic includ ulocuplumab
ulocuplumab monoclon antibodi
develop bristol-my multipl blood cancer indic
peptid antagonist develop
combin checkpoint inhibitor solid tumor biolinerx
develop number solid tumor partner mani
indic impact mavorixafor main program
could competit threat solid tumor space
mavorixafor antagonist know clinic
trial immunodefici disord attribut standard
focu much commun oncolog
diseas market overview
whim syndrom autosom domin genet diseas mutat
gene result truncat receptor turn result
inabl downregul stimul ultra-rar diseas
patient present wart hypogammaglobulinemia infect
myelokathexi whim wart may progress hpv-associ squamou
myelokathexi refer retent increas apoptosi matur
leukocyt bone marrow patient sever deplet
circul white blood cell neutrophil lymphocyt due
myelokathexi result low immunoglobulin level subsequ
current treatment includ immunoglobulin infus granulocyt
colony-stimul factor requir signific time invest
provid substanti better qualiti life chronic g-csf
administr correl myelofibrosi
patient treat off-label plerixafor anoth
antagonist develop sanofi plerixafor current evalu
nih head-to-head studi phase trial vs g-csf howev
see threat whim treatment registr trial
would requir studi plerixafor much shorter half-lif would
sever limit commerci set vs mavorixafor
mavorixafor breakthrough design orphan drug design
treatment whim patient
exhibit mavorixafor mechan whim syndrom
mavorixafor global phase registr trial whim syndrom
enrol patient random mavorixafor
placebo assess primari endpoint involv
neutrophil count cells/ul averag assess time
point secondari evalu includ infect rate wart burden
assess compani expect enrol subject
enrol complet sometim top-lin read-out
entrant confirm whim start trial mean
genet test trial particip year age
mavorixafor phase studi enrol eight patient open label
dual-cent dose-escal trial unit state australia
patient start escal side effect
minim present dri eye dri mouth nasal dryness
patient respond dose attain neutrophil
lymphocyt number respons given
drug clean safeti profil opt pursu dose
g-csf sometim use treat myelokathexi characterist
whim syndrom tri increas number neutrophil outsid
bone marrow g-csf effect lymphocyt type
white blood cell side effect g-csf includ disabl bone pain
myelofibrosi leukemia
immunoglobulin infus ivig also use patient
howev chronic treatment signific patient burden
come array potenti complic includ transfusion-
relat lung injuri hypertens anaphylaxi pain vomit among
scn rare diseas estim incid four per million peopl
popul genet transmit disord character
number genet mutat implic pathogenesi diseas
inherit pattern broad major patient
present genet mutat gene elan neutrophil
elastas autosom domin
appear subset scn patient would respond
antagon popul well defin understood
investig phase trial evalu exploratori
subset patient exploratori trial evalu potenti
respond scn compani announc evalu
potenti genet target given presenc
myelokathexi subpopul evalu scn broad
view especi attract potenti subpopul
defici associ anoth whim-lik syndrom term
wild syndrom wild stand wart immunodefici lymphedema
dysplasia
exhibit mavorixafor exploratori trial scn
g-csf use patient popul great effect
markedli improv patient durat qualiti life chronic g-csf use
correl high incid bone loss effect therapi
safe side effect profil still need patient popul
improv outcom fewer infect lower chanc sepsi
patient face higher preval aml/md adulthood
appear complic underli diseas may relat
g-csf use g-csf downstream signal still poorli understood
mutat gene code g-csf receptorar
relat leukemia scn patient may caus chronic g-csf
bone marrow transplant use last resort number
patient vari result procedur extrem costli put
signific burden patient
despit improv neutrophil number g-csf use mani
patient still succumb sepsi combin potenti
aml may induc chronic g-csf use clear new
improv therapi still need scn patient mavorixafor may play
greater role treatment scn project
waldenstrm macroglobulinemia lymphocyt lymphoma
malign lymphocyt continu produc immunoglobulin igm
result high level igm protein product patient develop
symptom relat bone marrow infiltr cancer
lymphocyt also igm excess bloodstream
autoantibodi interact igm may
approxim peopl us peopl eu
diagnos wm year patient whim-lik
mutat gene wm patient
genet mutat patient diagnosi waldenstrm
macroglobulinemia median expect surviv year
mutat gene typic wors prognosi
impair respons ibrutinib therapi patient greater
bone marrow involv higher igm level b-cell
sequest ibrutinib therapi believ rational strong
antagonist combo ibrutinib treatment subset
waldenstrm popul
exhibit rational mavorixafor wm
commerci certainli far away alreadi set
groundwork genet test popul partnership
whim syndrom believ possibl exist
evalu waldenstrm macroglobulinemia may allow earli
registr true would significantli boost price target
treatment current imbruvica chemotherapi rituxan
standard therapi wm recent ibrutinib
approv first-lin treatment
btk inhibitor could penetr marrow could threat
combo howev knowledg btk inhibitor exist
market clinic trial abil penetr bone marrow
competit concern horizon treatment
expect initi trial waldenstrm macroglobulinemia
immin includ patient mutat
fail prior therapi
renal cell carcinoma affect approxim peopl year
us popul clear cell renal cell carcinoma largest subset
affect patient present clear cell renal carcinoma
surgeri optim treatment patient popul cur
major patient metastas patient
undergo surgeri recurr resect tyrosin kinas
inhibitor tki sunitinib axitinib histor use howev
talk renal oncologist believ immuno-oncolog io
therapi continu promin use futur io/io
io/tki doublet doctor also suggest potenti role
renal cell treatment paradigm wait data
mavorixafor evalu combin axitinib phase trial
also evalu checkpoint inhibitor two phase
studi studi effect melanoma renal cell carcinoma
treatment landscap evolv doublet move first-lin
therapi given safeti mavorixafor may candid evalu
initi therapi member triplet combo
exhibit mavorixafor cancer
feasibl antagonist could role combin
therapi mani solid tumor howev yet antagonist
shown synergi checkpoint inhibitor tyrosin kinas inhibitor
true also mavorixafor shown data
demonstr superior current treatment yet see
subpopul may also better target antagonist
expect mavorixafor cancer agent use partner
asset larg pharma compani would receiv royalti
mileston expect up-front payment well
mileston year
success endeavor mavorixafor ccrcc exist
signific option move addit solid tumor type mani solid
tumor cancer involv includ ovarian pancreat
lung gastric colon prostat breast cancer
mani antagonist clinic design mani
inject peptid small molecul oral approach may
signific advantag design howev lack
visibl success solid tumor crowd solid tumor
landscap assign much valu mavorixafor solid tumor
view partnership signific option
design penetr blood-brain barrier order
potenti target glioblastoma read sever paper impli
potenti improv os patient
surgic resect tumor glioblastoma multiform see potenti
therapeut approach abl design molecul effect
design enhanc dose profil rel
mavorixafor compani doesnt expect improv mavorixafor
significantli simpli wish remov absorpt food effect
remov inhibit improv dose patient
march own exclus licens us patent
pend us patent direct product candid exclud
patent term extens composit matter mavorixafor expect
expir decemb howev orphan market exclus well
issu approv pend patent expect allow exclus
least
compani file opco research
compani file opco research
compani file opco research
mm except per share data fy us sales- upfront/milestones- total y/i growth gross gross margin sale oper oper oper marginn/an/an/an/an/an/an/an/an/an/an/an/an/an/atot incom expens interest incom chang fair valu warrants- loss extinguish debt- incom expens pre-tax incom pre-tax incom expens benefit tax rate incom sale dilut gaap y/i share y/i except per share data fy incom depreci deplet stock-bas compens chang work flow capit flow chang capit issuance/reduct debt flow net chang equival equival account prepaid expens current total current properti equip goodwill- right-of-us assets- total account accru expenses- current portion long-term debt- current total current long-term total common addit paid-in accumul comprehens retain total sharehold convert prefer stock- total liabil sharehold pharmaceut
dr ragan found hold posit
presid ceo director previous senior director
suppli chain diseas endocrin busi genzym
also senior director corpor develop genzym
diseas busi prior time genzym
senior director busi develop hydra bioscienc dr
ragan hold phd biomed engin mit also receiv
ms boston univers bioengin biomed
engin undergradu studi done tuft univers
mr mostafa cfo sinc septemb prior serv
cfo abpro held varieti invest bank role cantor
fitzgerald needham co citi graduat
brown univers bachelor degre econom
dr kelley sinc april prior
time histogen corpor well
inc time vice-president
medic affair senior medic director
dr kelley receiv md
dartmouth medic school gener surgeri
renato skerlj phdsvp
dr skerlj year experi capac biopharma
co-found join team
offici capac septemb dr skerlj director chemistri
anorm prior acquisit genzym mavorixafor
incept held varieti role drug discoveri
product develop anorm genzym recent
lysosom therapeut dr skerlj receiv phd synthet organ
chemistri univers british columbia complet two
postdoc one univers oxford anoth ohio state
tarek ebrahim mdvp medic affair diseas
dr ebrahim sinc novemb
held role medic affair diseas prior
time execut director global commerci
develop join alexion held
role increas respons genzym culmin role head
market us genet diseas dr ebrahim hold md
alexandria medic school human nutrit hold bsc medicin
surgeri
stock price compani mention report dec
co lly-nys cover
